comparemela.com

Latest Breaking News On - Rain oncology company profile - Page 1 : comparemela.com

Marquette Asset Management LLC Invests $73,000 in Rain Oncology Inc (NASDAQ:RAIN)

Marquette Asset Management LLC purchased a new position in shares of Rain Oncology Inc. (NASDAQ:RAIN – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 84,135 shares of the company’s stock, valued at approximately $73,000. Marquette Asset Management LLC owned 0.23% of […]

Rain Oncology Inc (NASDAQ:RAIN) Receives Average Recommendation of Hold from Analysts

Rain Oncology Inc. (NASDAQ:RAIN – Get Free Report) has earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat reports. Ten research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages […]

Rain Oncology Inc (NASDAQ:RAIN) Major Shareholder Kevin C Tang Purchases 131,631 Shares

Rain Oncology Inc. (NASDAQ:RAIN – Get Free Report) major shareholder Kevin C. Tang acquired 131,631 shares of the company’s stock in a transaction dated Friday, October 13th. The shares were bought at an average price of $0.99 per share, for a total transaction of $130,314.69. Following the acquisition, the insider now owns 4,024,486 shares in […]

Rain Oncology Inc (NASDAQ:RAIN) Receives $17 00 Consensus Price Target from Brokerages

Rain Oncology Inc. (NASDAQ:RAIN – Get Free Report) has earned an average rating of “Hold” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price […]

Brokerages Set Rain Oncology Inc (NASDAQ:RAIN) Price Target at $17 00

Shares of Rain Oncology Inc. (NASDAQ:RAIN – Free Report) have been assigned a consensus recommendation of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. Ten analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.